On March 6, 2018, the U.S. Food and Drug Administration (“FDA”) authorized, with special controls, the first direct-to-consumer test to detect the presence of genetic mutations in the BRCA1 and BRCA2 genes (“BRCA genes”). ...more
3/23/2018
/ 23andMe ,
Biotechnology ,
BRCA ,
Cancer ,
Direct to Consumer Sales ,
Food and Drug Administration (FDA) ,
Genetic Materials ,
Genetic Testing ,
Life Sciences ,
Patent-Eligible Subject Matter ,
Pharmaceutical Industry ,
Popular